Jinling Pharmaceutical Company Limited (SHE:000919)

China · Delayed Price · Currency is CNY

6.50

+0.07 (1.09%)

Sep 30, 2026, 3:04 PM CST

Market Cap	4.04B -5.1%
Revenue (ttm)	3.18B +0.4%
Net Income	55.96M +72.3%
EPS	0.09 +71.7%
Shares Out	621.92M
PE Ratio	72.22
Forward PE	n/a
Dividend	0.10 (1.54%)
Ex-Dividend Date	Jun 17, 2026

Volume	7,401,831
Open	6.49
Previous Close	6.43
Day's Range	6.42 - 6.53
52-Week Range	5.67 - 9.80
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 26, 2026

About SHE:000919

Jinling Pharmaceutical Company Limited, together with its subsidiaries, manufactures and sells pharmaceuticals and medical devices in China and internationally. It offers Mailuoning injection and oral solution for the treatment of thromboangiitis and arteriosclerosis obliterans, as well as cerebral and venous thrombosis; Sulifei, a ferrous succinate tablet for the prevention and treatment of iron deficiency anemia; Lentinan injection, an adjuvant therapy for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 5,716

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 000919

Full Company Profile

Financial Performance

In 2025, SHE:000919's revenue was 3.20 billion, a decrease of -2.56% compared to the previous year's 3.28 billion. Earnings were 53.91 million, an increase of 33.42%.

Financial Statements